Maria Stepanova, Khaled Kabbara, Denise Mohess, Manisha Verma, Alva Roche‐Green, Saleh AlQahtani, Janus Ong, Patrizia Burra, Zobair M. Younossi – 27 February 2022 – As the US population ages, more elderly patients may need liver transplantation. Our aim was to assess recent trends among elderly individuals requiring liver transplant in the United States. Scientific Registry of Transplant Recipients data (2002–2020) were used to select elderly (≥65 years) liver transplant candidates and assess on‐list and posttransplant outcomes.

Antonella Putignano, Thierry Gustot – 27 February 2022

Meng‐Ju Wu, Lei Shi, Joshua Merritt, Andrew X. Zhu, Nabeel Bardeesy – 27 February 2022 – Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause the IDH enzyme to aberrantly generate high levels of the oncometabolite, R‐2‐hydroxyglutarate, which competitively inhibits enzymes that regulate epigenetics, DNA repair, metabolism, and other processes. Among epithelial malignancies, IDH mutations are particularly common in intrahepatic cholangiocarcinoma (iCCA).

Jordyn Silverstein, Francis Y. Yao, Joshua D. Grab, Hillary J. Braun, John Roberts, Jennifer L. Dodge, Neil Mehta – 27 February 2022 – Living donor liver transplantation (LDLT) is an attractive option to decrease waitlist dropout, particularly for patients with hepatocellular carcinoma (HCC) who face lengthening waiting times. Using the United Network for Organ Sharing (UNOS) national database, trends in LDLT utilization for patients with HCC were evaluated, and post‐LT outcomes for LDLT versus deceased donor liver transplantation (DDLT) were compared.

Takeshi Goya, Kenichi Horisawa, Miyako Udono, Yasuyuki Ohkawa, Yoshihiro Ogawa, Sayaka Sekiya, Atsushi Suzuki – 26 February 2022 – Liver cancer is an aggressive cancer associated with a poor prognosis. Development of therapeutic strategies for liver cancer requires fundamental research using suitable experimental models. Recent progress in direct reprogramming technology has enabled the generation of many types of cells that are difficult to obtain and provide a cellular resource in experimental models of human diseases.

Abhinav Talwar, Jeffrey Varghese, Gabriel M. Knight, Nitin Katariya, Juan‐Carlos Caicedo, Zach Dietch, Daniel Borja‐Cacho, Daniella Ladner, Derrick Christopher, Talia Baker, Michael Abecassis, Samdeep Mouli, Kush Desai, Ahsun Riaz, Bart Thornburg, Riad Salem – 26 February 2022 – High‐grade portal vein thrombosis (PVT) is often considered to be a technically challenging scenario for liver transplantation (LT) and in some centers a relative contraindication.

Shunji Nagai, Anubhav Reddy Nallabasannagari, Dilip Moonka, Madhu Reddiboina, Sirisha Yeddula, Toshihiro Kitajima, Iman Francis, Marwan Abouljoud – 26 February 2022 – Current liver transplantation (LT) organ allocation relies on Model for End‐Stage Liver Disease–sodium scores to predict mortality in patients awaiting LT. This study aims to develop neural network (NN) models that more accurately predict LT waitlist mortality.

Roberta D’Ambrosio, Pietro Lampertico – 25 February 2022

Renumathy Dhanasekaran – 25 February 2022

Surain B. Roberts, Gideon M. Hirschfield, Lawrence J. Worobetz, Catherine Vincent, Jennifer A. Flemming, Angela Cheung, Karim Qumosani, Mark Swain, Dusanka Grbic, Hin Hin Ko, Kevork Peltekian, Nazia Selzner, Lusine Abrahamyan, Bishoi Aziz, Ellina Lytvyak, Kattleya Tirona, Aliya F. Gulamhusein, Harry L. A. Janssen, Aldo J. Montano‐Loza, Andrew L. Mason, Bettina E. Hansen, the Canadian Network for Autoimmune Liver Disease (CaNAL) – 25 February 2022